Triple

Target class: antiparkinsonian medication
Context triple: [Symmetrel, instanceOf, antiparkinsonian medication]

• A. aromatic L-amino acid decarboxylase inhibitor
  An aromatic L-amino acid decarboxylase inhibitor is a drug that blocks the enzyme responsible for converting aromatic L-amino acids (like levodopa) into their corresponding neurotransmitters, thereby increasing the availability of these precursors for therapeutic use, particularly in Parkinson’s disease.
• B. dopamine receptor antagonist
  A dopamine receptor antagonist is a drug that binds to dopamine receptors without activating them, thereby blocking dopamine’s effects and modulating neural signaling in conditions such as psychosis, nausea, and movement disorders.
• C. medication chosen
  A medication is a substance or combination of substances administered to diagnose, treat, prevent, or alleviate symptoms of disease or medical conditions in humans or animals.
• D. catechol-O-methyltransferase inhibitor
  A catechol-O-methyltransferase inhibitor is a drug that blocks the COMT enzyme to prevent the breakdown of catecholamines (such as dopamine), thereby prolonging and enhancing their effects, often used as an adjunct therapy in Parkinson’s disease.
• E. multiple sclerosis medication
  A multiple sclerosis medication is a drug or therapeutic agent designed to modify the disease course, manage relapses, or alleviate symptoms in individuals with multiple sclerosis by targeting immune or neurological processes.
• F. None of above.